54 results about "Left ventricular ejection" patented technology

A method for reversing ventricular dyssynchrony uses intracardiac echocardiographic measured parameters to systematically determine an optimal, individualized configuration for a cardiac resynchronization stimulator device. This method is particularly relevant for patients with congestive heart failure. The algorithm evaluates improvement in aortic flow and in left ventricular ejection fraction as atrioventricular and interventricular delay parameters of the patient's resynchronization stimulator device are varied.

A method for treating patients suffering from left ventricular dysfunction, exhibited by a left ventricular ejection fraction (LVEF) less than normal, is disclosed. The method involves applying, during diastole, for a time period of about one hour, about five days each week for at least about seven weeks, an incrementally increasing therapeutic pressure to the patients' lower extremities, from the calves through the thighs and the buttocks. The hourly treatments are carried out at incrementally increasing peak diastolic / systolic pressure ratios (D / S Ratios) in the range of about 0.4:1 up to about 0.6:1 and thereafter at a D / S Ratio in the range of 0.5:1 to 1:1 for each consecutive hourly treatment, with the proviso that the average D / S Ratio over the entire treatment regimen does not exceed about 0.9:1.

Heart failure with preserved ejection fraction (HFpEF) is a disease condition characterized by heart failure (HF) signs and symptoms, but with normal or near normal left ventricular ejection fraction (LVEF) and is not responsive to standard therapy for treatment of HF. Described herein are compositions and methods related to use of cardiosphere derived cells (CDCs) and their exosomes to improve left ventricular structure, function and overall outcome. Administration of CDCs led to improved LV relaxation, lower LV end-diastolic pressure, decreased lung congestion and enhanced survival. Lower risk of arrhythmias in HFpEF was also observed following CDC administration. Improvement of diastolic dysfunction following administration of CDC-derived exosomes was observed, along with decreased mortality. In view of these salutary effects, CDCs and CDC-derived exosomes are beneficial in the treatment of HFpEF.

The invention provides a therapeutic composition comprising an aqueous buffer, and a therapeutic agent that improves the functioning of a diseased heart by decreasing left ventricular end-diastolic pressure and simultaneously increasing left ventricular ejection without affecting the blood pressure or heart rate.

The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays (i.e., two or more hospital stays); (e) reducing the number of hospital admissions for heart failure; (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and / or the number of hospital visits); (g) increasing the left ventricular ejection fraction in a heart failure patient; (h) treating a sexual dysfunction (e.g., erectile dysfunction and female sexual dysfunction) (j) treating a headache in a heart failure patient by administering a non-steroidal antiinflammatory compound (i.e., NSAIDs); (k) treating a heart failure patient who has a history of hypertension (but who is not currently diagnosed with hypertension); (l) improving the quality of life in a heart failure patient based on the Minnesota Living with heart failure questionnaire; (m) decreasing the levels of B-type natriuretic peptide; (n) treating hypertension in a heart failure patient; (o) lowering blood pressure in a heart failure patient; (p) treating labile hypertension; (q) treating idiopathic hypertension; (r) increasing patient compliance with medication dosing in a heart failure patient; (s) treating hypertension in a patient with a dilated heart; (t) treating ischemic disease and / or coronary artery disease; and (u) reducing cardiomegaly in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and / or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.

An active implantable medical device such as a cardiac prosthesis for the treatment of a heart failure by controlled adjustment of the atrioventricular and interventricular delays. The device provides atrioventricular and / or biventricular stimulation, a sensor delivering at least one hemodynamic parameter correlated with time intervals representative of the succession of the systolic and diastolic phases, and circuits to adjust the AV delay and / or VV delay. The device determines (12) during one cardiac cycle several parameters such as the left ventricular pre-ejection interval LPEI, the left ventricular ejection time LVET, the diastolic filling time FT and the conduction time PR. The device compares (14, 18) these parameters with at least one predetermined criterion. If a condition is met, the device readjusts (16) the AV delay and / or VV delay to maximize the ventricular filling and ejection.

The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and / or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and / or isosorbide mononitrate.

Present application relates to methods for determining whether a subject has heart failure or is at risk of having heart failure, specifically that of heart failure with reduced left ventricular ejection fraction (HFREF) and a heart failure with preserved left ventricular ejection fraction (HFPEF), comprising determining the level of selected miRNA(s) observed in a sample obtained from the subjectand wherein an altered level of the miRNA(s) compared to control indicates that the subject has heart failure or is at risk of developing heart failure. Also encompassed are methods of determining analtered risk of death or disease progression to hospitalization and death based on alteration of selected miRNAs in a sample from the subject and kits thereof.

In an implantable medical device for detecting and / or monitoring the progression of diastolic heart failure (DHF), and a corresponding method, a parameter is measured that is indicative of left ventricular ejection fraction (LVEF), and a variable is also measured that is indicative of the workload of the patient, and a relation is determined between LVEF and the workload, and DHF is detected and / or the progression of DHF is monitored, dependent on this relation.

A system for detecting dehydration, hemorrhaging, and increases in blood volume comprising monitors the time difference between the arrival of the primary left ventricular ejection pulse (pulse T1) and the arrival of the iliac reflection (pulse T3) to determine an arterial pulse parameter which is the time difference between T1 T3. Changes in T3 minus T1 are indicative of something happening to blood volume. If the T1-3 value goes up and the patient is on an infusion system, it can be an indication of having too much fluid pumped and if T1-3 is lower than it should be for an individual, they are either dehydrated (which can result in decreases in blood volume), they are hemorrhaging, or they have hemorrhaged. A downtrend in T13 can tell whether someone is continuing to hemorrhage

A system for detecting dehydration, hemorrhaging, and increases in blood volume comprising monitors the time difference between the arrival of the primary left ventricular ejection pulse (pulse T1) and the arrival of the iliac reflection (pulse T3) to determine an arterial pulse parameter which is the time difference between T1 T3. Changes in T3 minus T1 are indicative of something happening to blood volume. If the T1−3 value goes up and the patient is on an infusion system, it can be an indication of having too much fluid pumped and if T1−3 is lower than it should be for an individual, they are either dehydrated (which can result in decreases in blood volume), they are hemorrhaging, or they have hemorrhaged. A downtrend in T13 can tell whether someone is continuing to hemorrhage

The invention discloses an ante partum new-born baby risk predicting method for a heart disease pregnant patient, a system and a medium. The method comprises the steps of performing data screening andcharacteristic extraction on pre-acquired medical data of a congenital heart disease pregnant patient and a new-born baby, and acquiring an influence factor which corresponds with a production risk;performing single-factor logistic regression analysis on the influence factor, and screening all variables with probability p smaller than a preset threshold; performing multiple-factor logistic regression analysis on all the screened variables, and establishing a logistic regression model; inputting a left ventricular ejection fraction, a left atrial diameter, a left ventricular diameter, an ascending aorta inner diameter, pulmonary artery systolic pressure and pulmonary artery average pressure into the logistic regression model, thereby obtaining an ante partum new-born baby risk evaluationresult of a to-be-predicted target.

The invention consists of a device and method for the prediction of left ventricular ejection fraction (EF) and other cardiac hemodynamic parameters using systolic time intervals in patients with narrow QRS, right bundle branch block, left bundle branch block, right ventricular and / or left ventricular cardiac pacing and in the presence of arrhythmia, such as atrial fibrillation. The device has three inputs: the ECG, a peripheral pulse and a phonocardiogram. Timing parameters are obtained from these signals to calculate a systolic function index, used for the prediction of ejection fraction. Given the invention's features it would be now possible to assess cardiac performance and specifically left ventricular ejection fraction in ambulatory patients as well as during invasive procedures such as the implant of cardiac rhythm management devices. Also, an implantable embodiment of the invention would allow constant monitoring of cardiac performance, parameter adjustment of cardiac devices and automatic drug infusion.

The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and / or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and / or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

The invention provides a therapeutic composition comprising an aqueous buffer, and a therapeutic agent that proves the functioning of a diseased heart by decreasing left ventricular end-diastolic pressure and simultaneously increasing left ventricular ejection without affecting the blood pressure or heart rate.

The invention relates to the technical field of biomedical engineering and provides a use of a RyR2 protein or a RyR2 recombinant protein in preparation of an anti-heart failure drug. The RyR2 recombinant protein is a fragment or a mutant of a natural RyR2 protein, such as a SPRY1 structural domain protein, a P1 structural domain protein, a SPRY2 structural domain protein, a SPRY3 structural domain protein, a Handle structural domain protein, a HD1 structural domain protein, a HD2 structural domain protein, a central structural domain protein, an EF-hand structural domain protein, a U-type motif protein, a P2 structural domain protein, a P2 structural domain fragment protein 1, a P2 structural domain fragment protein 2 or a P2 mutant of the natural RyR2 protein. The exogenous RyR2 recombinant protein has a high expression level in normal small animal models and small animal disease models so that the left ventricular ejection fractions of the experimental animals are increased to different extents compared with the control group, the disease model animals are able to reduce the beta-adrenergic-induced ventricular tachyarrhythmia to varying degrees and the ventricular function of each treatment group is recovered to varying degrees.

Heart failure with preserved ejection fraction (HFpEF) is a disease condition characterized by heart failure (HF) signs and symptoms, but with normal or near normal left ventricular ejection fraction (LVEF) and is not responsive to standard therapy for treatment of HF. Described herein are compositions and methods related to use of cardiosphere derived cells (CDCs) and their exosomes to improve left ventricular structure, function and overall outcome. Administration of CDCs led to improved LV relaxation, lower LV end-diastolic pressure, decreased lung congestion and enhanced survival. Lower risk of arrhythmias in HFpEF was also observed following CDC administration. Improvement of diastolic dysfunction following administration of CDC-derived exosomes was observed, along with decreased mortality. In view of these salutary effects, CDCs and CDC-derived exosomes are beneficial in the treatment of HFpEF.

The invention discloses a heart failure detection method based on combined semantic technology and medical image segmentation. The method comprises the following steps: segmenting the inner membrane and the outer membrane of a left ventricle magnetic resonance image; calculating a segmentation result so as to convert image information into triple information; storing the triple information into a heart failure body established by protete; and then, automatically detecting the state of a heart by the powerful reasoning function of a semantic technology. According to the heart failure detection method based on the combined semantic technology and medical image segmentation, an input heart magnetic resonance image sequence is subjected to myocardial mass calculation and left ventricular ejection fraction calculation almost without manual intervention, the extraction precision of the inner membrane and the outer membrane of a left ventricle can be greatly improved, wrong segmentation brought by a fact that the extraction of an inner membrane profile and an outer membrane profile is affected by papillary muscles and an artifact can be reduced.

A method for treating patients suffering from left ventricular dysfunction is disclosed. The method involves applying, during diastole, for a time period of about one hour, at least five days each week for at least about six weeks, an incrementally increasing external therapeutic pressure sequentially to the patients' lower extremities from first the calves, then the thighs and last the buttocks. The initial hourly treatments are carried out at a peak diastolic / systolic pressure ratio (D / S Ratio) in the range of about 0.4:1 up to about 0.9:1, depending on the patient's left ventricular ejection fraction. The D / S Ratio is increased slightly during the next set of hourly treatments, the D / S Ratio is again increased slightly during the next following set of hourly treatments, the D / S Ratio is again increased slightly during the next set of hourly treatments, and finally the D / S Ratio is increased slightly and maintained during the remaining set of hourly treatments. The patient's cardiopulmonary functions preferably are monitored to determine if additional external therapeutic pressure treatments are needed.

The invention discloses an application of multi-type mixed cells in myocardial infarction cell treatment, wherein the multi-type mixed cells are cells derived from vein bridge vessels after a vein istransplanted to an artery. The invention also provides the application of the multi-type mixed cells as a medicament for preventing or treating myocardial infarction. When the multi-type mixed cell disclosed by the invention is applied to myocardial infarction treatment, the cardiac function after myocardial infarction can be improved, the left ventricular ejection fraction can be increased, the infarct area and the wall thickness can be reduced, and the inner diameter of the ventricle can be reduced, so that symptoms can be improved, and the application has important clinical significance.

The diagnostic support apparatus detects a pulse waveform from an animate being, and measures the time difference between the arrival of a first pulse and the arrival of a second pulse. The first pulse, is the primary left ventricular ejection pulse, and corresponds to the first peak and the second pulse, is the iliac reflection pulse and corresponds to the third peak. Data storage can be provided for storing measured time differences between the first and the second pulses for a period of at least about fifteen real time seconds to produce statistically significant arterial pulse parameter data represented by the time difference. Data relating to blood volume and / or blood volume changes are monitored to show trend changes relative to a baseline value.

The invention provides an application of ganoderma spore oil to preparation of a cardiovascular disease prevention and treatment medicine. A ligated left coronary artery induced hypertension heart disease model is used for analyzing cardiac functions by taking ventricular wall thicknesses in a contraction period and a relaxation period, inner diameter data, left ventricular ejection fraction and the like as observation indexes, results indicate that separate active components including the ganoderma spore oil extracted from ganoderma spores can improve the cardiac functions under the condition of effective dose 3g / (kg*BW), ejection fraction reaches 66.02 and approximates blank control group values, heart blood output quantity is effectively improved, particularly, left ventricular relaxation capacity is obviously changed, and the ganoderma spore oil has the function of preventing cardiovascular diseases and can be used for preparing the cardiovascular disease prevention and treatment medicine.

The invention is a method for controlled regional reperfusion using ATP-MgCl2 after percutaneous coronary revascularization for acute myocardial infarction, the method comprising the step of administering an effective amount of ATP-MgCl2 to the step of administering an effective amount of ATP-MgCl2 to the infarct-related vessel(s), such as at a dosage level of at least 0.03 mg / kg / min. The method also includes a method for controlled regional reperfusion using ATP-MgCl2 after percutaneous coronary revascularization for acute myocardial infarction, the method comprising the steps of (a) performing cardiac catheterization and coronary angiogram; (b) identifying the infarct-related vessel; (c) performing a left ventriculogram and calculating the left ventricular ejection fraction; and (d) performing a percutaneous coronary intervention; and after percutaneous revascularization of the infarct related vessel, infusing ATP-MgCl2 intracoronary, preferably at a rate of at least 0.03 mg / kg / min through the balloon catheter.

The invention discloses a medicine for treating heart qi deficiency, blood stasis and edema syndromes of chronic cardiac failure and a preparation method of the medicine. The medicine is prepared such medicinal raw materials as astragali radix, roasted rhizoma atractylodis macrocephalae, dried ginger, prepared leech, roasted semen plantaginis, poria cocos, roasted fructus aurantii immaturus, roasted semen lepidii and raw liquorice. The medicine has the beneficial effects that compared with internationally recognized treatment by use of Western medicines hydrochlorothiazide and acertil, sugar-free granules, which are developed based on the traditional Chinese medicine theory of correlation between heart and spleen, according to the treatment rules of warning heart and spleen, promoting circulation of fluid and expelling stasis and by use of a class 6 new traditional Chinese medicine preparation process, are capable of obviously improving the LVEF (Left Ventricular Ejection Fraction) and the LVFS (Left Ventricular Fractional Shortening) of chronic cardiac failure suffering rats, and therefore, the whole and radius contraction functions of the left ventricles of the rats having the heart qi deficiency, blood stasis and edema syndromes can be obviously improved; the medicine has the trend of improving the load of the left ventricles of the rats having the heart qi deficiency, blood stasis and edema syndromes by reducing the BNP (Brain Natriuretic Peptide) blood concentration, and therefore, the diastolic function of the left ventricles of the rats having the heart qi deficiency, blood stasis and edema syndromes can be improved. The medicine has the advantages of remarkable curative effect, no toxic and side effects and the like.

The invention belongs to the technical field of medical treatment, and provides a capacity management device and equipment for emergency treatment and a storage medium. The device comprises a heart evaluation unit which is used for evaluating whether a patient has an organic heart disease according to an image of a heart apex four-cavity heart tangent surface; a parameter determination unit, which is used for determining a left ventricular ejection fraction LVEF value according to the image of the long-axis section beside the sternum and determining the maximum inner diameter of the inferior vena cava and the collapse rate of the inferior vena cava according to the image of the inferior vena cava section under the xiphoid process when the patient is assessed to have no organic heart disease; a score calculation unit which is used for determining scores corresponding to the left ventricular ejection fraction LVEF value, the inferior vena cava maximum inner diameter and the inferior vena cava collapse rate; and a liquid management scheme determination unit which is used for searching a liquid management scheme corresponding to the determined score and carrying out volume management on the patient according to the searched liquid management scheme. According to the method, the cardiac organic safety problem of the patient can be effectively avoided, and the liquid management scheme of the patient can be simply, efficiently, safely and accurately determined.

The invention consists of a device and method for the prediction of left ventricular ejection fraction (EF) and other cardiac hemodynamic parameters using systolic time intervals in patients with narrow QRS, right bundle branch block, left bundle branch block, right ventricular and / or left ventricular cardiac pacing and in the presence of arrhythmia, such as atrial fibrillation. The device has three inputs: the ECG, a peripheral pulse and a phonocardiogram. Timing parameters are obtained from these signals to calculate a systolic function index, used for the prediction of ejection fraction. Given the invention's features it would be now possible to assess cardiac performance and specifically left ventricular ejection fraction in ambulatory patients as well as during invasive procedures such as the implant of cardiac rhythm management devices. Also, an implantable embodiment of the invention would allow constant monitoring of cardiac performance, parameter adjustment of cardiac devices and automatic drug infusion.

A method for treating patients suffering from left ventricular dysfunction is disclosed. The method involves applying, during diastole, for a time period of about one hour, at least five days each week for at least about six weeks, an incrementally increasing external therapeutic pressure sequentially to the patients' lower extremities from first the calves, then the thighs and last the buttocks. The initial hourly treatments are carried out at a peak diastolic / systolic pressure ratio (D / S Ratio) in the range of about 0.4:1 up to about 0.9:1, depending on the patient's left ventricular ejection fraction. The D / S Ratio is increased slightly during the next set of hourly treatments, the D / S Ratio is again increased slightly during the next following set of hourly treatments, the D / S Ratio is again increased slightly during the next set of hourly treatments, and finally the D / S Ratio is increased slightly and maintained during the remaining set of hourly treatments. The patient's cardiopulmonary functions preferably are monitored to determine if additional external therapeutic pressure treatments are needed.

A system and a method for identifying a patient with a threshold number of distinct ECG abnormalities. The system and the method include an ECG monitoring device; a server; a database; a network; a memory containing machine readable medium comprising a machine executable code having stored thereon instructions for identifying patients with a threshold number of distinct ECG abnormalities; and a processor coupled to the memory, the processor configured to execute the machine executable code to cause the processor to: receive an ECG data output from the ECG monitoring device; process the ECG data output to identify abnormalities in the ECG data; and analyze the abnormalities in the ECG data in order to output an indication of whether the patient has depressed LVEF, wherein the ECG monitoring device, the server, the database, the memory, and the processor are coupled to the network via communication links.